The weekly litigation news digest is live. Subscribe now

IP Verse

Combination Therapy For Prostate Cancer - EP3609497

The patent EP3609497 was granted to Janssen Pharmaceutica on Oct 12, 2022. The application was filed on Apr 9, 2018 under application number EP18720895A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3609497

JANSSEN PHARMACEUTICA
Application Number
EP18720895A
Filing Date
Apr 9, 2018
Status
Granted And Under Opposition
Sep 9, 2022
Publication Date
Oct 12, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Antitumor drugs for men with metastatic castration-resistant prostate cancer (mCRPC). The drugs are niraparib, abiraterone acetate, and prednisone in a total amount that is therapeutically effective for the treatment of a prostate cancer in a human patient.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
GENERICS UKJul 12, 2023RUSSELLADMISSIBLE
SANDOZJul 11, 2023ELKINGTON AND FIFEADMISSIBLE
TEVA PHARMACEUTICALSJul 6, 2023VON KAUFFMANNADMISSIBLE

Patent Citations (5) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS8071623
DESCRIPTIONUS8436185
INTERNATIONAL-SEARCH-REPORTUS2014336157
OPPOSITIONUS2014336157
OPPOSITIONWO2008084261

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents